Navigation Links
Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
Date:10/31/2007

n of action is believed to relate to diminished affinity for the natriuretic peptide clearance receptor and increased resistance to the enzyme neutral endopeptidase, both pathways for clearance of endogenous natriuretic peptides. In animal models, PL-3994 was able to induce diuresis (excretion of fluids) with a limited decrease in blood pressure. The compound is well absorbed by the subcutaneous route of administration.

About Congestive Heart Failure (CHF)

Currently in the U.S., CHF affects nearly 5 million people and 550,000 new cases of CHF will be diagnosed this year. Despite the treatment of CHF with multiple drugs, almost all CHF patients will experience at least one episode of acute CHF that requires treatment with intravenous medications in the hospital. Congestive heart failure has tremendous human and financial costs. Annual medical expenditures for CHF are estimated to be $28.8 billion.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. The Company's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. The Company currently has collaborations with AstraZeneca and the Mallinckrodt division of Covidien. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Statements about the Company's future expectations, including statements about its development programs, the significance of the results of clinical trials, the conduct of future clinical trials, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, a
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
3. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Minn. , Jan. 14, 2014   NuAire , a manufacturer ... to agreement with Hitachi Koki of Japan ... in North America . NuAire will utilize its ... and Canada to offer assistance in ...
(Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Corporation (Nasdaq: IRIX ) today announced that management ... 23rd Annual OC Growth Stock Conference on Monday, March 14, ... March 13-16 at the Ritz Carlton Laguna Niguel in Dana ... live webcast on the Investor section of IRIDEX,s website at: ...
... Medical Devices strengthened its executive team with the appointment ... Joseph Lee, Xeridiem Medical Devices, President said, "I am ... Medical Devices as Vice-President Business Development, effective March 1, ... design and development services with a focus on sales ...
Cached Medicine Technology:Xeridiem Medical Devices Appoints Renae Moomjian, Vice President, Business Development 2
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... The American Physical Therapy Association (APTA) is urging ... physical therapist, in light of a new federal survey ... nearly 12 percent of children use alternative medicine ... for treatment. Results of the 2007 survey of more ...
... 15, 2008 A program at Washington University School ... Hospital designed to increase awareness about sickle cell disease ... faith community led to a 60 percent increase in ... The program, called Sickle Cell Sabbath, was formally launched ...
... Statement , , VIRGINIA BEACH, ... AGP ) announced today that it filed a universal shelf ... Commission on December 15, 2008. The registration statement enables the ... debt, common stock, preferred stock and other securities at prices ...
... for Fighting AIDS joins PEPFAR, Nike Foundation, Coca-Cola Africa Foundation ... , NAIROBI, Kenya, Dec. 15 ... in Nairobi will rely on Rotarians for Fighting AIDS (RFFA) ... and economic development opportunities. , , ...
... Dec. 15 Streamline Health Solutions, Inc. (Nasdaq: STRM ) today announced ... 31, 2008. , , Highlights of the quarter and ... Revenues increased 11% versus comparable quarter in the previous ... 31, 2007 , Year-to-date company has won 8 ...
... of the American,Association of Drilling Engineers (AADE) recently ... to advance cancer research. The funds will,be used ... surgeon,Eugene Kim. The research program is focused on ... neuroblastoma, a deadly pediatric cancer. , ...
Cached Medicine News:Health News:Physical therapy offers evidence-based solution to musculoskeletal pain 2Health News:Church effort sharply increases first-time African-American blood donors 2Health News:AMERIGROUP Files Shelf Registration Statement 2Health News:Rotary Action Group Helps Launch Major Public-Private HIV Prevention Initiative in Kenya 2Health News:Rotary Action Group Helps Launch Major Public-Private HIV Prevention Initiative in Kenya 3Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 2Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 3Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 4Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 5Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 6Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 7Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 8Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 9Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 10Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 11Health News:Drilling Engineers Donate $35,000 to Texas Children's Hospital 2
ApolipoproteinA-1 & B Calibrator...
CRP Calibrator...
Fructosamine controls level 3...
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Medicine Products: